Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Takahashi K, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M; Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association. Saeki H, et al. Among authors: yotsuyanagi h. J Dermatol. 2023 May;50(5):e138-e150. doi: 10.1111/1346-8138.16797. Epub 2023 Apr 1. J Dermatol. 2023. PMID: 37132187
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Sano S, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M; Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association. Saeki H, et al. Among authors: yotsuyanagi h. J Dermatol. 2023 Feb;50(2):e41-e68. doi: 10.1111/1346-8138.16691. Epub 2022 Dec 29. J Dermatol. 2023. PMID: 36582113
The third nationwide surveillance of antimicrobial susceptibility against Neisseria gonorrhoeae from male urethritis in Japan, 2016-2017.
Yasuda M, Takahashi S, Miyazaki J, Wada K, Kobayashi K, Matsumoto M, Hayami H, Yamamoto S, Kiyota H, Sato J, Matsumoto T, Yotsuyanagi H, Hanaki H, Masumori N, Hiyama Y, Nishiyama H, Kimura T, Yamada H, Matsumoto K, Ishikawa K, Togo Y, Tanaka K, Sadahira T, Inokuchi J, Hamasuna R, Ito K, Hirayama H, Hayashi K, Kurimura Y, Kadena H, Ito S, Shiono Y, Maruyama T, Ito M, Hatano K, Chokyu H, Ihara H, Uno S, Monden K, Yokoyama T, Kano M, Kaji S, Kawahara M, Sumii T, Tojo T, Hosobe T, Naito K, Kawai S, Nishimura H, Izumitani M, Yoh M, Matsumura M, Fujita R, Takayama K, Hara M, Nishi S. Yasuda M, et al. Among authors: yotsuyanagi h. J Infect Chemother. 2023 Nov;29(11):1011-1016. doi: 10.1016/j.jiac.2023.08.003. Epub 2023 Aug 6. J Infect Chemother. 2023. PMID: 37553046
A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19.
Miyazaki T, Hosogaya N, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Ozawa Y, Shiko Y, Inaba Y, Kurokawa T, Hanaoka H, Iwanami S, Kim K, Iwami S, Watashi K, Miyazawa K, Umeyama T, Yamagoe S, Miyazaki Y, Wakita T, Sumiyoshi M, Hirayama T, Izumikawa K, Yanagihara K, Mukae H, Kawasuji H, Yamamoto Y, Tarumoto N, Ishii H, Ohno H, Yatera K, Kakeya H, Kichikawa Y, Kato Y, Matsumoto T, Saito M, Yotsuyanagi H, Kohno S. Miyazaki T, et al. Among authors: yotsuyanagi h. Microbiol Spectr. 2023 Jun 15;11(3):e0431122. doi: 10.1128/spectrum.04311-22. Epub 2023 May 4. Microbiol Spectr. 2023. PMID: 37140398 Free PMC article. Clinical Trial.
Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination.
Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y. Yamamoto S, et al. Among authors: yotsuyanagi h. iScience. 2023 Jun 25;26(7):107208. doi: 10.1016/j.isci.2023.107208. eCollection 2023 Jul 21. iScience. 2023. PMID: 37448563 Free PMC article.
Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Fukushi S, Watanabe S, Suzuki T, Kikuchi T, Yotsuyanagi H, Maeda K, Kawaoka Y. Uraki R, et al. Among authors: yotsuyanagi h. iScience. 2023 Oct 4;26(11):108147. doi: 10.1016/j.isci.2023.108147. eCollection 2023 Nov 17. iScience. 2023. PMID: 37876803 Free PMC article.
Corrigendum to "The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan" [J. Infect. Chemother. 29 (2023) 143-149].
Ohnishi T, Watanabe S, Matsumoto T, Yotsuyanagi H, Sato J, Kobayashi I, Iinuma S, Nagayama T, Shibuya S, Ogawa N, Iozumi K, Nakajima Y, Kurikawa Y, Kobayashi M, Matsuo K, Ishikawa H, Shimizu T, Tsutsui K, Kawamura T, Okuyama R, Seishima M, Akita Y, Kasugai C, Yano K, Tamada Y, Mizutani K, Kabashima K, Yamada N, Ikeda M. Ohnishi T, et al. Among authors: yotsuyanagi h. J Infect Chemother. 2023 Jun;29(6):634-635. doi: 10.1016/j.jiac.2023.03.014. Epub 2023 Mar 22. J Infect Chemother. 2023. PMID: 37005215 No abstract available.
Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Uraki R, et al. Among authors: yotsuyanagi h. Lancet Infect Dis. 2023 May;23(5):525-526. doi: 10.1016/S1473-3099(23)00132-9. Epub 2023 Mar 7. Lancet Infect Dis. 2023. PMID: 36898405 Free PMC article. No abstract available.
258 results